About Us
Science Programs
Pipeline
Clinical Trials
Careers
cONTACT
Resources
Corporate Presentation
Posters, PRESENTATIONS & Publications
MEDIA
Events
News & press releases
Investors
Overview
Stock Information
Analyst Coverage
Stock Quote & Chart
Historical Price Lookup
Investment Calculator
Financials & SEC FILINGS
Sec Filings
Quarterly Results
cORPORATE GOVERNANCE
Management Team
Board of Directors
Committee Composition
Governance Documents
News & Press Releases
Get up to speed with Rain!
Filter by year...
2022
2021
2020
2019
2018
Reset Filter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
September
3
,
2020
Rain Therapeutics to Present at Citi’s 15th Annual BioPharma Virtual Conference
Download PDf
September
3
,
2020
Rain Therapeutics Closes $63 Million Series B Financing
Download PDf
September
2
,
2020
Rain Therapeutics Announces Exclusive License to the Clinical-Stage MDM2 Inhibitor, DS-3032 (Milademetan) from Daiichi Sankyo
Download PDf
August
25
,
2020
Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors in the DNA Damage Response Pathway
Download PDf
May
13
,
2019
Rain Therapeutics to Present at the UBS Global Healthcare Conference
Download PDf
April
3
,
2019
Rain Therapeutics Presents Preclinical Data on Lead Candidate Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting
Download PDf
April
2
,
2019
Rain Therapeutics Presents Preclinical Activity of Tarloxotinib in NRG1 Fusion Cancers at the Annual American Association for Cancer Research (AACR) Meeting
Download PDf
March
19
,
2019
Rain Therapeutics Announces First Patient Dosed in Phase 2 Trial of Tarloxotinib for the Treatment of Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertion or HER2-Activating Mutations
Download PDf
February
28
,
2019
Rain Therapeutics to Present Data on Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting 2019
Download PDf
November
6
,
2018
Rain Therapeutics to Present Data on Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting 2019
Download PDf
Previous
#
Next
